Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

Abstract The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-val...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hsin-Yi Huang, Shin-Yi Lin, Shou-Hsia Cheng, Chi-Chuan Wang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
R
Q
Acceso en línea:https://doaj.org/article/f39f53d69007441bb6454079715716c7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f39f53d69007441bb6454079715716c7
record_format dspace
spelling oai:doaj.org-article:f39f53d69007441bb6454079715716c72021-12-02T15:08:55ZEffectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study10.1038/s41598-018-21884-y2045-2322https://doaj.org/article/f39f53d69007441bb6454079715716c72018-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-21884-yhttps://doaj.org/toc/2045-2322Abstract The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-valvular atrial fibrillation under warfarin or rivaroxaban therapy were included. Propensity score matching was used to balance the covariates, and Cox-proportional hazard models were applied to compare the effectiveness and safety of each treatment group. Rivaroxaban was associated with a significantly lower risk of venous thromboembolism (hazard ratio [HR]: 0.51; 95% confidence interval [CI]: 0.29–0.92, P = 0.02) and intracranial hemorrhage (HR: 0.48; 95% CI: 0.32–0.72, P < 0.001) than warfarin. Rivaroxaban 20 mg and 15 mg were associated with a significantly lower risk of ischemic stroke (20 mg, HR: 0.48; CI: 0.29–0.80, P = 0.005; 15 mg, HR: 0.69; CI: 0.53–0.90, P = 0.005), but rivaroxaban 10 mg was not. In the subgroup analysis of patients older than 65 years, the results were generally the same, except that rivaroxaban had a significantly lower risk of ischemic stroke than warfarin.Hsin-Yi HuangShin-Yi LinShou-Hsia ChengChi-Chuan WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Hsin-Yi Huang
Shin-Yi Lin
Shou-Hsia Cheng
Chi-Chuan Wang
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
description Abstract The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-valvular atrial fibrillation under warfarin or rivaroxaban therapy were included. Propensity score matching was used to balance the covariates, and Cox-proportional hazard models were applied to compare the effectiveness and safety of each treatment group. Rivaroxaban was associated with a significantly lower risk of venous thromboembolism (hazard ratio [HR]: 0.51; 95% confidence interval [CI]: 0.29–0.92, P = 0.02) and intracranial hemorrhage (HR: 0.48; 95% CI: 0.32–0.72, P < 0.001) than warfarin. Rivaroxaban 20 mg and 15 mg were associated with a significantly lower risk of ischemic stroke (20 mg, HR: 0.48; CI: 0.29–0.80, P = 0.005; 15 mg, HR: 0.69; CI: 0.53–0.90, P = 0.005), but rivaroxaban 10 mg was not. In the subgroup analysis of patients older than 65 years, the results were generally the same, except that rivaroxaban had a significantly lower risk of ischemic stroke than warfarin.
format article
author Hsin-Yi Huang
Shin-Yi Lin
Shou-Hsia Cheng
Chi-Chuan Wang
author_facet Hsin-Yi Huang
Shin-Yi Lin
Shou-Hsia Cheng
Chi-Chuan Wang
author_sort Hsin-Yi Huang
title Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
title_short Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
title_full Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
title_fullStr Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
title_full_unstemmed Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
title_sort effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study
publisher Nature Portfolio
publishDate 2018
url https://doaj.org/article/f39f53d69007441bb6454079715716c7
work_keys_str_mv AT hsinyihuang effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy
AT shinyilin effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy
AT shouhsiacheng effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy
AT chichuanwang effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy
_version_ 1718387975199391744